[{"address1": "301 Binney Street", "address2": "Suite 402", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 401 9975", "website": "https://www.synlogictx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.", "fullTimeEmployees": 6, "maxAge": 86400, "priceHint": 4, "previousClose": 1.53, "open": 1.52, "dayLow": 1.45, "dayHigh": 1.5283, "regularMarketPreviousClose": 1.53, "regularMarketOpen": 1.52, "regularMarketDayLow": 1.45, "regularMarketDayHigh": 1.5283, "beta": 1.001, "forwardPE": -11.461539, "volume": 39237, "regularMarketVolume": 39237, "averageVolume": 26219, "averageVolume10days": 25530, "averageDailyVolume10Day": 25530, "marketCap": 17443430, "fiftyTwoWeekLow": 0.234, "fiftyTwoWeekHigh": 5.708, "priceToSalesTrailing12Months": 5.442568, "fiftyDayAverage": 1.7113, "twoHundredDayAverage": 2.153745, "currency": "USD", "enterpriseValue": -403553, "floatShares": 3619691, "sharesOutstanding": 11707000, "sharesShort": 9113, "sharesShortPriorMonth": 35580, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0008, "heldPercentInsiders": 0.15568, "heldPercentInstitutions": 0.60674, "shortRatio": 0.31, "shortPercentOfFloat": 0.0022, "impliedSharesOutstanding": 11707000, "bookValue": 1.146, "priceToBook": 1.3001745, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -73224000, "trailingEps": -8.02, "forwardEps": -0.13, "lastSplitFactor": "1:7", "lastSplitDate": 1503878400, "enterpriseToRevenue": -0.126, "enterpriseToEbitda": 0.008, "52WeekChange": 2.5560858, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SYBX", "underlyingSymbol": "SYBX", "shortName": "Synlogic, Inc.", "longName": "Synlogic, Inc.", "firstTradeDateEpochUtc": 1443619800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "30bbb3c7-ab0a-33b2-91a8-e57d2c890111", "messageBoardId": "finmb_268899196", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.49, "targetHighPrice": 1.0, "targetLowPrice": 1.0, "targetMeanPrice": 1.0, "targetMedianPrice": 1.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 32311000, "totalCashPerShare": 2.76, "ebitda": -47745000, "totalDebt": 14464000, "quickRatio": 2.953, "currentRatio": 3.194, "totalRevenue": 3205000, "debtToEquity": 108.548, "revenuePerShare": 0.382, "returnOnAssets": -0.47755, "returnOnEquity": -1.78515, "freeCashflow": -20154250, "operatingCashflow": -45545000, "revenueGrowth": -0.954, "grossMargins": 1.0, "operatingMargins": -1319.5, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]